GuangDong South Land pharmaceutical Listed by ransomhouse Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On 10 October 2024 the ransomware group ransomhouse listed GuangDong South Land pharmaceutical on its leak site, claiming it had exfiltrated internal files in a ransomware attack. Public detail on the incident remains limited: the number of people affected is unknown, and the precise contents of the files have not been independently confirmed. For anyone whose personal, employment or business information may sit inside those files, the practical stakes are straightforward—possible exposure of data that could be misused for fraud, targeted phishing or other harm, and the need to take basic protective steps while waiting for clearer information.

Because the listing is a claim by the group rather than a verified disclosure from the company, the full scope and confirmation of any breach are still unconfirmed. That uncertainty itself creates risk: people connected to the organisation cannot yet know whether their records were involved and must therefore act on the possibility rather than on definitive notice.

What happened

According to the public listing, ransomhouse claims to have carried out a ransomware attack against GuangDong South Land pharmaceutical and to have exfiltrated internal files. The listing was reported on 10 October 2024. No further technical details—such as the initial access method, the duration of any intrusion, the volume of data taken, or any ransom demand—have been disclosed in the available record. The number of people affected is listed as unknown. The only data description provided is “internal files exfiltrated in ransomware attack.” Independent verification of the claim has not been reported, so the incident should be treated as an unverified assertion by the threat actor until additional evidence appears.

Who is ransomhouse?

Ransomhouse is a ransomware operation that has been publicly documented since roughly 2021–2022. Like many contemporary groups, it typically follows a double-extortion model: encrypting systems while also stealing data and threatening to publish or sell it if a ransom is not paid. The group maintains a leak site on which it posts victim names and, in some cases, sample files or larger data dumps. Public reporting has associated ransomhouse with attacks across multiple sectors and geographies; its operators have been observed using standard ransomware tooling, data-exfiltration techniques and pressure tactics common to the broader ransomware ecosystem. Nothing in the public record of this particular listing goes beyond the group’s claim that it holds internal files from GuangDong South Land pharmaceutical; any additional statements the group may have made about this victim are not part of the What's Publicly Reported available here.

Who is GuangDong South Land pharmaceutical?

GuangDong South Land pharmaceutical (also referred to in available descriptions as Nan guo Pharmaceutical) is a pharmaceutical manufacturer based in the Fenton Industrial Zone of Zhanjiang, China. Public information states that it has developed a digital intelligent production base and operates dozens of modern pharmaceutical production workshops. It is described as one of the pharmaceutical companies in the country with the largest number of products and the most complete range of dosage forms. Organisations of this type routinely handle employee records, supplier and partner data, production and quality-control documentation, regulatory filings, and sometimes patient- or clinical-related information depending on their product lines. A claimed breach at such a firm therefore raises concerns not only for internal staff and commercial partners but also for the integrity of manufacturing and supply-chain information that underpins medicine production.

The information in question

The only data type named in the available facts is “internal files exfiltrated in ransomware attack.” No inventory of specific categories—such as employee personal data, customer lists, financial records, research files or production formulas—has been published. Exact contents therefore remain unconfirmed. Pharmaceutical manufacturers typically hold a mix of human-resources data, commercial contracts, manufacturing process documents, quality-assurance records and regulatory correspondence. Whether any of those categories were among the files claimed by ransomhouse cannot be established from the public record. Until a fuller disclosure appears, the prudent assumption is that any internal material the company stored electronically could theoretically be involved, but that remains an assumption rather than a verified fact.

The real-world impact

For individuals whose data may have been taken, the concrete risks include phishing or social-engineering attempts that use accurate internal details, identity-related fraud if personal identifiers were present, and longer-term exposure if the files later appear on criminal markets. Because the number of people affected is unknown, the circle of potentially impacted parties—employees, contractors, suppliers or others—cannot yet be defined. For the organisation itself, a ransomware incident of this kind can disrupt production systems, delay regulatory or commercial processes, and create reputational and contractual pressure even before any data is published. The absence of confirmed scale or content means both the human and operational consequences are still uncertain; the main immediate effect is the need for heightened vigilance by anyone connected to the company.

Were you affected?

If you have a past or present relationship with GuangDong South Land pharmaceutical—as an employee, contractor, supplier or other contact—treat the possibility of exposure seriously until clearer information emerges. Monitor financial and email accounts for unusual activity, enable multi-factor authentication where available, and be sceptical of unexpected messages that reference the company or request sensitive information. Consider changing passwords for any accounts that reused credentials linked to work systems. You can also run a free exposure scan of your email address to check whether it has already appeared in known breach data sets; such a scan will not confirm or rule out involvement in this specific incident, but it can surface other exposures that warrant attention. Stay alert for any official notification from the company or relevant authorities, and treat unsolicited offers of “help” recovering data with caution.

AICompiled with AI assistance from public sources and published under our editorial standards.